Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?

This phase 2 trial is investigating whether giving immunotherapy before surgery for advanced melanoma (stage IIIB to IV M1a) can maintain survival while allowing patients to skip the usual adjuvant therapy after surgery. Participants are randomly assigned to receive either two infusions of pembrolizumab or a combination of ipilimumab plus nivolumab followed by a single nivolumab infusion. The study will track overall survival at two years and event-free survival at one year to see if this neoadjuvant approach is as effective as the standard path.